ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 996,64
0,49%
Dow Jones
38 852,27
0,46%
DAX
18 175,21
1,01%
Brent Oil
83,595
0,14%
Bitcoin
63 574,58
0,65%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Actualités

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:AIM
DateHeureSourceTitreSymboleSociété
06/05/202414h30GlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
29/04/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
25/04/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
15/04/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
10/04/202414h21GlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
02/04/202413h30GlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
28/03/202413h05GlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
26/03/202414h05GlobeNewswire Inc.AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
25/03/202414h05GlobeNewswire Inc.AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAMEX:AIMAIM ImmunoTech Inc
15/03/202413h45GlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityAMEX:AIMAIM ImmunoTech Inc
07/03/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Launch of CEO Corner PlatformAMEX:AIMAIM ImmunoTech Inc
29/02/202414h45GlobeNewswire Inc.AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateAMEX:AIMAIM ImmunoTech Inc
21/02/202416h37Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
20/02/202422h34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:AIMAIM ImmunoTech Inc
20/02/202422h31Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
14/02/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
08/02/202414h50GlobeNewswire Inc.AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAMEX:AIMAIM ImmunoTech Inc
24/01/202415h10GlobeNewswire Inc.AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
22/01/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
10/01/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
05/01/202419h32Business WireAIM Shareholders Elect All Four Company Director Nominees at 2023 Annual MeetingAMEX:AIMAIM ImmunoTech Inc
03/01/202422h24Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AIMAIM ImmunoTech Inc
03/01/202422h24Edgar (US Regulatory)Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialAMEX:AIMAIM ImmunoTech Inc
03/01/202422h05PR Newswire (US)Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly DeniedAMEX:AIMAIM ImmunoTech Inc
29/12/202314h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:AIMAIM ImmunoTech Inc
29/12/202314h00Business WireDelaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are InvalidAMEX:AIMAIM ImmunoTech Inc
28/11/202322h30Business WireAIM ImmunoTech Provides Update Regarding Annual MeetingAMEX:AIMAIM ImmunoTech Inc
27/11/202318h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
27/11/202315h05GlobeNewswire Inc.AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. PatentsAMEX:AIMAIM ImmunoTech Inc
21/11/202318h00GlobeNewswire Inc.AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM

Dernières Valeurs Consultées

EU
CS
Axa
NYSE
MRK
Merck
EU
CAP
Capgemini
EU
PX4
SBF 120
FTSE
UKX
FTSE 100
EU
VIV
Vivendi
EU
AI
Air Liquide
EU
ACA
Credit Agricole
EU
DG
Vinci
COIN
ETHUSD
Ethereum
EU
SGO
Cie de SaintGobain
EU
GLE
Societe Generale
EU
BN
Danone
EU
EN
Bouygues
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés